Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Gender-affirming hormone therapy may increase heart disease risk in transgender individuals.

Properly administered testosterone therapy is safe and effective but often not covered by insurance.

Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

Gender-affirming hormone therapy affects health risks and requires careful management, especially as transgender individuals age.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

The treatment successfully lowered testosterone levels and reduced symptoms.

New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.

Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

Treat hirsutism in premenopausal women with oral contraceptives and consider additional treatments if needed.

The treatment reduced hair growth and testosterone in women with excess hair and had some effects on stress responses.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Hormonal therapy is a treatment option for acne, the only medical treatment for hirsutism, and the most promising for androgenetic alopecia.

Goserelin and oestradiol treatment slightly improved hairiness but did not significantly change sebum production or hair characteristics in mildly hirsute women.

A postmenopausal woman's facial redness, acne, and excess hair were caused by too much hormone therapy for insomnia, but improved after stopping the treatment.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.

Transgender and gender-diverse adults on hormone therapy often face drug-hormone interactions, especially with multiple psychotropic medications.

Cheap treatments for excessive hair growth in women can improve symptoms by 35-40% after one year.